Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
davoceticept
- Development stage
- Discontinued
- Lead developer
- Vertex
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Davoceticept (ALPN-202) is a first-in-class, conditional CD28 costimulator and dual immune checkpoint inhibitor developed for the treatment of cancer. It is an Fc fusion protein composed of a variant immunoglobulin domain of CD80 fused to a human IgG1 Fc fragment. Davoceticept is designed to provide tumor-localized, PD-L1-dependent CD28 co-stimulation while simultaneously inhibiting both the PD-L1 and CTLA-4 immune checkpoints. This tri-functional mechanism aims to enhance antitumor immunity by activating T cells in the tumor microenvironment while blocking inhibitory signals that suppress immune responses. The drug has been evaluated as monotherapy (NEON-1 trial) and in combination with pembrolizumab (NEON-2 trial) in adults with advanced solid tumors or lymphoma[2][3][5][6].
- Other names
- davoceticept
02
Targets
CD28 (Cluster of Differentiation 28)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on davoceticept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on davoceticept.